EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

ADP ‐ribosylation: An emerging regulator of the epigenome

Cristel V Camacho iD, Chenqian Liu iD, W Lee Kraus iD

Molecular Oncology · 2026

DOI: 10.1002/1878-0261.70317 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Oncology, 2026. Verfasst von Cristel V Camacho und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Signaling and Gene Regulation, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medica…. Hauptthemen laut MEDLINE: ADP-Ribosylation, Epigenome, Epigenesis, Genetic. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Prevention and Research Institute of Texas, U.S. DOD Ovarian Cancer Research Program, Burroughs Wellcome Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ADP‐ribosylation (ADPRylation) is a post‐translational modification best known for its roles in DNA damage responses and cytoplasmic signaling, but it also serves important functions in epigenome regulation. In the nucleus, ADPRylation modulates chromatin structure and gene expression through the coordinated modification of histones and chromatin‐associated proteins. Although poly(ADP‐ribosyl)ation (PARylation) has dominated the field, particularly as therapeutic targets in DNA repair deficient malignancies, a gap remains in our understanding of how mono(ADP‐ribosyl)ation (MARylation)—mediated by mono(ADP‐ribosyl) transferases (MARTs)—functions as a discrete, site‐specific epigenomic mark. Nuclear MART‐mediated ADPRylation modulates the activity, localization, and complex assembly of epigenomic enzymes, and directly modifies histones to influence chromatin accessibility and transcriptional dynamics. These reversible modifications intersect with canonical epigenomic marks, enabling rapid, context‐dependent control of gene expression. Emerging studies further implicate dysregulated nuclear ADPRylation in cancer, where altered MARylation of chromatin regulators and transcription factors contributes to aberrant gene expression programs and may represent a novel class of therapeutic vulnerabilities. In this review, we synthesize emerging insights into nuclear ADPRylation, with a focus on MART‐mediated regulation of histones and chromatin enzymes, and discuss how this regulatory layer expands current models of epigenomic control in physiology and how its alterations drive oncogenesis, offering novel, nonsynthetically lethal avenues for targeted cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADP-RibosylationEpigenomeEpigenesis, GeneticHumansAnimalsHistonesNeoplasmsChromatinProtein Processing, Post-Translational

Stichwörter der Autor:innen

ADP‐ribosylation (ADPRylation)chromatin remodeling complexgene regulationhistonehistone modifying enzymestranscriptiontranscription factor

Substanzen

HistonesChromatin

Autor:innen und Institutionen

  • Laboratory of Signaling and Gene Regulation, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, USA.
  • Division of Basic Research, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, USA.

ORCID-Profile: Cristel V Camacho, Chenqian Liu, W Lee Kraus

Förderung

  • Cancer Prevention and Research Institute of Texas
  • U.S. DOD Ovarian Cancer Research Program
  • Burroughs Wellcome Fund
  • NIDDK NIH HHS
  • NCI NIH HHS
  • NIH National Cancer Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Camacho, C. V., Liu, C., & Kraus, W. L. (2026). ADP ‐ribosylation: An emerging regulator of the epigenome. Molecular Oncology. https://doi.org/10.1002/1878-0261.70317

Vancouver

Camacho CV, Liu C, Kraus WL. ADP ‐ribosylation: An emerging regulator of the epigenome. Molecular Oncology. 2026. doi:10.1002/1878-0261.70317

BibTeX
@article{Camacho2026,
  author = {Camacho, Cristel V and Liu, Chenqian and Kraus, W Lee},
  title = {ADP ‐ribosylation: An emerging regulator of the epigenome},
  journal = {Molecular Oncology},
  year = {2026},
  doi = {10.1002/1878-0261.70317}
}
Kostenlos starten →